[go: up one dir, main page]

AU7709300A - Drug discovery using gene expression profiling - Google Patents

Drug discovery using gene expression profiling

Info

Publication number
AU7709300A
AU7709300A AU77093/00A AU7709300A AU7709300A AU 7709300 A AU7709300 A AU 7709300A AU 77093/00 A AU77093/00 A AU 77093/00A AU 7709300 A AU7709300 A AU 7709300A AU 7709300 A AU7709300 A AU 7709300A
Authority
AU
Australia
Prior art keywords
gene expression
drug discovery
expression profiling
profiling
discovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU77093/00A
Inventor
Yih Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Linden Technologies Inc
Original Assignee
Linden Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linden Technologies Inc filed Critical Linden Technologies Inc
Publication of AU7709300A publication Critical patent/AU7709300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/20—Heterogeneous data integration
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU77093/00A 1999-09-24 2000-09-22 Drug discovery using gene expression profiling Abandoned AU7709300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15610599P 1999-09-24 1999-09-24
US60156105 1999-09-24
PCT/US2000/026050 WO2001020998A1 (en) 1999-09-24 2000-09-22 Drug discovery using gene expression profiling

Publications (1)

Publication Number Publication Date
AU7709300A true AU7709300A (en) 2001-04-24

Family

ID=22558115

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77093/00A Abandoned AU7709300A (en) 1999-09-24 2000-09-22 Drug discovery using gene expression profiling

Country Status (2)

Country Link
AU (1) AU7709300A (en)
WO (1) WO2001020998A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
KR20040064275A (en) 2001-11-09 2004-07-16 소스 프리시전 메디슨, 인코포레이티드 Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
WO2004007681A2 (en) * 2002-07-12 2004-01-22 Duke University Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes
US7807465B2 (en) 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7790390B2 (en) 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7524926B2 (en) 2005-01-20 2009-04-28 Biomarck Pharmaceuticals, Ltd. Mucin hypersecretion inhibitors and methods of use
ZA200900550B (en) 2006-07-26 2010-03-31 Biomarck Pharmaceuticals Ltd Methods for attenuating release of inflammatory mediators and peptides useful therein
WO2020257162A1 (en) 2019-06-17 2020-12-24 Biomarck Pharmaceuticals Ltd. Peptides and methods of use thereof in treating uveitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114114A (en) * 1992-07-17 2000-09-05 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
WO1999001581A1 (en) * 1997-07-02 1999-01-14 Genzyme Corporation P53 influenced gene expression
AU9200298A (en) * 1997-08-22 1999-03-16 Yale University A process to study changes in gene expression in stem cells
AU9200398A (en) * 1997-08-22 1999-03-16 Yale University A process to study changes in gene expression in granulocytic cells
EP1075485A4 (en) * 1998-05-05 2004-12-15 Gene Logic Inc METHOD FOR STUDYING MODIFICATIONS OF GENE EXPRESSION IN T CELLS
JP2002530092A (en) * 1998-11-13 2002-09-17 キュラゲン コーポレイション Compositions and methods related to the peroxisome proliferator-activated receptor-α-mediated pathway

Also Published As

Publication number Publication date
WO2001020998A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
AU1071301A (en) Pharmaceutical compounds
AU5259100A (en) Medicament
AU3569800A (en) Pyrimidine compounds with pharmaceutical activity
AU2002259196A1 (en) Gene expression profiling
AU1469001A (en) Capacitive mouse
AU6281100A (en) Novel diketopiperazines
AU7815000A (en) Targeted drug activation
AUPP938799A0 (en) Electrodes
AU5073400A (en) Sulfonamide compounds with pharmaceutical activity
AU1132601A (en) Feature interactions
AU6715600A (en) Pharmaceutical formulations
AU1586500A (en) Computer arrangement using non-refreshed dram
AUPQ262599A0 (en) Gene expression
AU7709300A (en) Drug discovery using gene expression profiling
AU1645700A (en) Oenothein medicaments
AU4977300A (en) Pharmaceutical formulations
AU1348601A (en) Modular computer
AU5722900A (en) Pharmaceutical compounds
AU6036100A (en) New pharmaceutically active compounds
AU1385801A (en) Pharmaceutical formulations
AU7606100A (en) Gene expression profiles
EP1144631A3 (en) Insulin-synthesis genes
AU7318700A (en) Novel transaldolase gene
AU2732000A (en) Reverse gene therapy
AU2001247444A1 (en) Erbeta-mediated gene expression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase